GSK initiates Phase III programme of daprodustat

UK drug manufacturer GlaxoSmithKline (GSK) has initiated its Phase III programme of daprodustat being developed to treat anaemia associated with chronic kidney disease (CKD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news